China's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distribution

Shanghai Haohai Biological Technology

21/08/2026 14:25

Overview
China biomedical products maker's half-year revenue fell 9.8% yr/yr to RMB1.17 bln
Net profit attributable to shareholders dropped 46.6% yr/yr for the six-month period
Company cut interim dividend to RMB0.25 per share from RMB0.40 last year

Outlook
 Shanghai Haohai expects hydrophilic and hydrophobic EDOF IOL approvals in H2 2026
Group will accelerate clinical trials for long-acting sodium hyaluronate, chitosan and stem-cell intra-articular injections

Result Drivers
 MEDICAL AESTHETICS PRESSURE – Weak domestic demand and price competition cut HA Dermal Filler revenue 41.59% to RMB202.01 mln, weighing on revenue and margin
DISTRIBUTION EXIT AND NEW PRODUCTS – End of Brighten Optix distribution cut lens revenue RMB23.16 mln; regeneration products added RMB61.09 mln, partly offsetting declines
R&D EXPENSES - Co reduced R&D expenses by 3.1% yr/yr to RMB95.39 mln

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 1.17 bln
 

Analyst Coverage
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 7 three months ago

Reuters Recommended Reads
Aug 20 - China's 3SBio H1 net profit falls on higher expenses
Aug 20 - China's CSPC Pharmaceutical H1 revenue rises on finished drug business growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)